MAPT and Alzheimer disease: One tau PET tracer (that is, [18F]flortaucipir/Tauvid) has received approval from the US Food and Drug Administration for clinical use to support a clinical diagnosis of AD18, because it (and other tau PET tracers) can accurately distinguish between AD dementia and most other (non-AD) neurodegenerative disorders19,20.